First patient dosed in clinical trial of oral treatment for Parkinson’s

Study testing Mission Therapeutics' therapy recruiting in several locations

Written by Andrea Lobo | Oct. 19, 2026

• The first patient was dosed in a Phase 1b clinical trial testing MTX325, an oral treatment for Parkinson’s.
• The trial is still recruiting participants at several locations.
• MTX325 aims to be a disease-modifying therapy by improving mitochondrial quality control through the blocking of the USP30 enzyme.

The first patient has been dosed in Mission Therapeutics’ Phase 1b clinical trial of MTX325, an oral treatment for Parkinson’s disease.

With several locations open in the U.K., France, Germany, and Australia, the Phase 1b clinical trial (NCT07630545) is still recruiting up to 36 adults aged 40-75 with mild to moderate idiopathic (of unknown cause) Parkinson’s.

The first patient was dosed at the Royal Liverpool University Hospital in the U.K. Initial data are expected in 2027.

The start of this part of the trial follows the successful completion of an earlier part conducted in healthy volunteers, which showed that the treatment was generally safe and could reach functional brain tissue.

“Dosing the first Parkinson’s disease patient is a significant milestone in the development of MTX325, a potential disease-modifying treatment for this serious neurodegenerative disease,” Sarah Fritchley, PhD, Mission’s chief development officer, said in a company press release.